Mylan Faces Another Class Action Lawsuit Over EpiPen Pricing

Mylan has been in the news a lot lately, and now that it’s facing a “new proposed class action lawsuit over the price of its EpiPen allergy treatment,” the company is bound to be in the news even more in coming months. The lawsuit was filed by three EpiPen purchasers on Monday in Tacoma, Washington federal court, claiming that “Mylan engaged in a scheme with pharmacy benefit managers (PBMs).” What are PBMs? They’re “companies that act as intermediaries between pharmacies, insurers and drug companies – to dominate the market and overcharge consumers.”




Cheaper Healthcare: Waste Not, Want Less

While President Trump might not have realized how complex fixing healthcare could be, pretty much everyone else had some idea. What people may not fully realize is that the private sector isn’t as virtuously free of the kinds of waste, fraud, and abuse that are typically attributed only to government. Putting a dent in these money pits would go a long way towards bringing cheaper healthcare to desperate people.